Merck (NYSE:MRK) reported new Phase 3 data for belzutifan based WELIREG regimens in renal cell carcinoma, showing meaningful ...

Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio. Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio ...

After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...

Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

Tempus AI Inc. on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. aimed at accelerating AI-driven ...

Merck KGaA (MKGAF) stock drops as the company projects a disappointing revenue and adjusted EBITDA outlook for 2026. Read more here.

The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and ...